Reporter brief
RCT of immunotherapy plus senolytics versus control before head and neck cancer surgery
What happened
A Phase II randomised controlled trial evaluated tislelizumab (anti-PD-1 antibody) combined with dasatinib and quercetin (senolytics) as neoadjuvant therapy before surgery in patients with head and neck squamous cell carcinoma. The trial assessed efficacy and safety of this combined immunotherapy-senolytic approach.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Other; Human.
Patients with head and neck squamous cell carcinoma who are about to undergo surgery
- Design
- Other
- Sample
- —
- Journal
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Published
- Sep 19, 2024
Effect size
Not recorded.
Caveats
- Assessment: Pending.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.